Fusion protein based on Grb2-SH2 domain for cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Epidermal growth factor receptor (EGFR) is a key target in cancer therapy.
• Grb2 adaptor protein mediates EGFR signaling, crucial for tumor growth.
• Disrupting EGFR-Grb2 interaction is a potential therapeutic strategy.

Purpose of the Study:

• To create and evaluate fusion proteins (TSF, TSSF) designed to inhibit EGFR-Grb2 signaling.
• To assess the efficacy of these fusion proteins in blocking downstream signaling and suppressing tumor growth.

Main Methods:

• Generation of fusion proteins incorporating Grb2 SH2 domains and HIV-1 TAT for cell penetration.
• Assessment of protein binding affinity to phosphorylated EGFR.
• Evaluation of effects on p42-ERK phosphorylation in EGFR-overexpressing cells.
• In vitro cell growth assays and in vivo tumor growth suppression studies.

Main Results:

• TSSF demonstrated higher binding affinity to EGFR compared to TSF.
• TSSF significantly reduced p42-ERK phosphorylation, unlike TSF.
• Both proteins inhibited cell growth in vitro but did not induce cell death.
• TSSF significantly suppressed tumor growth in vivo.

Conclusions:

• TSSF effectively inhibits EGFR-Grb2 signaling pathway.
• TSSF shows potential as a therapeutic agent for EGFR-activated cancers.
• Fusion protein design offers a promising approach for targeted cancer therapy.